Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;41(9):751-755.
doi: 10.1007/s40261-021-01068-9. Epub 2021 Aug 5.

Tirbanibulin: Topical Treatment for Actinic Keratosis

Anna H Dlott  1 , Anthony J Di Pasqua  2 , Sara A Spencer  3
Affiliations
Review

Tirbanibulin: Topical Treatment for Actinic Keratosis

Anna H Dlott et al. Clin Drug Investig. 2021 Sep.

Abstract

We review here the pharmacology, pharmacokinetics, efficacy, dosage and administration, and place in therapy of tirbanibulin for the treatment of actinic keratosis (AK). A literature search using PubMed was conducted using the terms tirbanibulin (tirbanibulin) and actinic keratosis from September 2014 to February 2021. All English-language articles evaluating tirbanibulin were analyzed for this review. Tirbanibulin was granted approval for the treatment of AK of the face or scalp as a first-line therapy. It is administered at a dose of 2.5 mg in 250 mg of white or off-white ointment for a 25 cm2 contiguous treatment surface for 5 consecutive days. Adverse effects include flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. This article discusses the clinical trials that led to the approval of tirbanibulin and comparison with other approved topical ointments indicated for the treatment of AK. In the clinical trials, all participants experienced a decrease in lesion size or saw complete clearance with minimal adverse effects.

PubMed Disclaimer

References

    1. Tirbanibulin; Lexicomp Online Databases. Hudson: Lexicomp; 2021.
    1. Full prescribing information: Klisyri. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf .
    1. FDA approves Klistri. Drugs.com. 2020. https://www.drugs.com/newdrugs/fda-approves-klisyri-tirbanibulin-actinic... . Accessed 7 July 2021.
    1. Yavel R, Overcash SJ, Zhi J, Cutler E, Cutler DL, Fang J. Phase 1 maximal use pharmacokinetics study of tirbanibulin ointment 1% in subjects with actinic keratosis. https://jofskin.org/index.php/skin/article/view/1092/pdf.7 Accessed 7 July 2021.
    1. Richard MA, Amici JM, Basset-Seguin N, Claudel JP, Cribier B, Dréno B. Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam of expert clinicians. J Eur Acad Dermatol Venereol. 2021;2018(28):339–46. https://doi.org/10.1111/jdv.14753.Accessed7Jul . - DOI

MeSH terms

LinkOut - more resources